<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00147836</url>
  </required_header>
  <id_info>
    <org_study_id>NECT-2004-WJP</org_study_id>
    <secondary_id>GSTB-05100981-LYB</secondary_id>
    <nct_id>NCT00147836</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients</brief_title>
  <official_title>Evaluation of the Effects of Oral Anti-Hyperglycemic Agents, Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion on Glycemic Control, B-Cell Function and the Remission Rate in Newly-Diagnosed Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Education, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Science and Technology Bureau, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate and evaluate the effects of different
      interventions (1.continuous subcutaneous insulin infusion,2.multiple daily injections,
      3.anti-hyperglycemic agents) on glycemic control, B-cell function and the remission rate in
      newly-diagnosed type 2 diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ß-Cell dysfunction and decreased insulin sensitivity are the main pathophysiological defects
      responsible for the development of hyperglycemia. With continuous presence of insulin
      resistance, progressive loss of ß-cell function is the crucial defect. Hyperglycemia has
      deleterious effect on β-cell function, which is partially reversible by adequate glycemic
      control. In newly diagnosed type 2 diabetic patients with severe hyperglycemia, 2 weeks
      continuous subcutaneous insulin infusion (CSII) can induce adequate glycemic control with
      improvement of β-cell function. Nearly half of the patients can maintain euglycemia longer
      than 12 months by transient CSII. The improvement of β-cell function, especially the
      restoration of the first-phase insulin response is related to sustained euglycemia in the
      newly diagnosed type 2 diabetic patients. But it is unclear whether any other interventions
      (such as oral hypoglycemic agents and multiple daily injections) inducing optimal glycemic
      control in a short period of time can have the same effect. As a multicenter, open-label,
      randomized, parallel-group study will be needed to further prove and clarify the findings.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glycemic control, the improvement of β-cell l function and the remission rate after short intensive therapy in newly diagnosed type 2 diabetic patients</measure>
    <time_frame>Oct. 2007</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the effects of different interventions (oral anti-hyperglycemic agents, multiple daily injections and continuous subcutaneous insulin infusion) on glycemic control, β-cell function and the remission rate in newly-diagnosed type 2 diabetic patients</measure>
    <time_frame>Oct. 2007</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">436</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>CSII</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in continuous subcutaneous insulin infusion group received Human Insulin (Novolin-R, Novo Nordisk) with an insulin pump (H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland);</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in MDI group were treated with pre-meal Novolin-R, and Human Insulin NPH (Novolin-N, Novo Nordisk) at bedtime. Initial insulin doses were 0.4-0.5 IU/kg and total daily doses were divided into 50% of basal and 50% of bolus injection in CSII group and 30%-20%-20%-30% in multiple daily insulin injection group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OHA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In oral hpoglycemic agents group, the patients with 20 kg/m2&lt;BMI≤25kg/m2 were initiated with Gliclazide (Diamicron, Servier) 80mg Bid (maximum to 160mg Bid), the patients with 25kg/m2&lt;BMI≤35kg/m2 were initiated with Metformin (Glucophage, BMS) 0.5 Bid (maximum to 2.0g/d), the combination of Diamicron and Glucophage was used in patients who could not achieve glycaemic control goal with one OHA or with FPG≥11.1mmol/l at randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Insulin (Novolin-R, Novo Nordisk)</intervention_name>
    <arm_group_label>CSII</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland</intervention_name>
    <arm_group_label>CSII</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pre-meal</intervention_name>
    <arm_group_label>MDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Novolin-R</intervention_name>
    <arm_group_label>MDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Insulin NPH (Novolin-N, Novo Nordisk)</intervention_name>
    <arm_group_label>MDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gliclazide (Diamicron, Servier)</intervention_name>
    <arm_group_label>OHA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diamicron and Glucophage</intervention_name>
    <arm_group_label>OHA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. informed consents be given before treatment

          2. the newly-diagnosed type 2 diabetic patients

          3. fasting blood glucose (FBG) level ranging from 7.0～16.7 mmol/L

          4. age ranging from 25～70 years old

          5. body mass index (BMI) ranging from20～35kg/m2

          6. never be treated with any anti-hyperglycemic agents or anti-hyperlipidemic agents

        Exclusion Criteria:

          1. having any severe acute or chronic complications

          2. renal dysfunction, blood creatinine≥150µmol/L

          3. blood aminotransferase level rising up(more than 2 times of the normal level)

          4. any severe cardiac disease including congestive cardiac failure, unstable angina and
             myocardial infarct in 12 months

          5. serious hypertension (systolic pressure≥180mmHg and/ or diastolic pressure≥110mmHg)

          6. chronic or acute pancreatic disease

          7. severe systematic diseases or malignant tumor

          8. allergic to the drugs using in the trial

          9. any factors interfering the result

         10. female patients incline to be pregnant

         11. being treated with corticosteroid, immunosuppressing drugs or cytotoxic drugs

         12. poor compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianping Weng, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ministry of Education</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>the first Affiliated Hospital of Sun Yat-Sen university</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng J. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care. 2004 Nov;27(11):2597-602.</citation>
    <PMID>15504992</PMID>
  </reference>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2005</study_first_submitted>
  <study_first_submitted_qc>September 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>March 31, 2008</last_update_submitted>
  <last_update_submitted_qc>March 31, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2008</last_update_posted>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>therapy</keyword>
  <keyword>sulfonylureas</keyword>
  <keyword>metformin</keyword>
  <keyword>insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

